EUCTR2020-005052-37-PL招募中1 期
Optymalizacja czasu leczenia i dawkowania wemurafenibu u maloletnich pacjentów z opornymi na konwencjonalna terapie rozrostami z komórek histiocytarnych z obecnoscia mutacji w genie BRAF. - BRAVO
Institute of Mother and Child0 个研究点目标入组 25 人开始时间: 2021年1月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.The presence of mutations in the BRAF gene in tumor tissues and/or in ctDNA at any stage of treatment or follow-up.
- •2.Failure of the treatment (at least one of below needs to apply in order for this requirement to be satisfied):
- •a. Progression on the I and/or II line treatment, including at least one risk organ; prior treatment should include a minimum of 6 weeks of weekly Vinblastine with a minimum of 28 days prednisolone or minimum 2 cycles of Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a 2nd line treatment, minimum 2 cycles, or other second-line treatment or
- •b. Disease reactivation after an initial response to treatment with Vimblastine and prednisolone as the first line and/or no response to second line treatment using one of two drugs: Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles, minimum 2 cycles, or other I/ II line treatment or occurrence of involvement of at least one risk organ or
- •c. Third or subsequent reactivation of disease with or without risk organ involvement, or
- •d. Reactivation of disease after Vemurafenib therapy has been completed, or
- •e. The appearance of signs of neurodegenerative disorder (ND) in MRI of the CNS.
- •3. Signing of informed consent for trial participation (including for Vemurafenib treatment) according with current legal regulations.
- •4. Consent to the use of effective contraception throughout the Vemurafenib administration period and a minimum of 1 year after discontinuation in patients at puberty and sexual maturity.
- •5. Participation in HISTIOGEN trial.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 25
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Lack of inclusion criteria.
- •2. Pregnancy and breastfeeding .
- •3. Hypersensitivity to the study drug or any of its ingredients.
- •4. Iritis, uveitis, obstruction of the retinal veins.
- •5. Simultaneous treatment with other drugs which might interact with Vemurafenib.
- •6. Persistent toxicity related to prior therapy, making it impossible to treat with Vemurafenib.
- •7. Diagnosis of other malignancies before study inclusion.
- •8. Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator’s opinion, disqualify a patient from participating in the trial.
研究者
相似试验
招募中
2 期
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisHistiocytosisNCT04943198Anna Raciborska25
招募中
2 期
To test the safety, efficacy and tolerability of a drug called trametinib and determine the duration of treatment in children with histiocytic cell hyperplasia refractory to conventional therapy.2024-515896-37-00Instytut Matki I Dziecka12
已完成
不适用
Study of blood level of lifesaving antibiotic meropenum in serious ICU patients in relation to blood level that kills bacteria.CTRI/2013/07/003850Tata Memorial Hospital25
已完成
3 期
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trialR65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shockDRKS00011159Friedrich-Schiller-Universität Jena254
尚未招募
不适用
Defining the optimal dose for continuous flucloxacillin infusioNL-OMON28330Deventer Hospital30